Pfizer

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Pfizer sits in the top decile of US sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count).

1,845 total trials 106 currently recruiting 1335 completed early-phase tilt top decile by trial count

Pfizer: 1,845 sponsored US clinical trials, 106 recruiting.

Pfizer sponsors 1,845 registered US clinical trials on ClinicalTrials.gov, 106 of them currently recruiting, and 1,335 completed. 504 of these trials are in Phase 3-4 (later-stage) and 1,173 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 44 trials.

Top-decile sponsor footprint

Pfizer ranks in the top decile of sponsors by registered trial count (#7 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 39/100

1,335 of 1,673 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,845 total, page 27 of 37

TERMINATED Phase 4

Study Evaluating The Safety Of Xyntha In Usual Care Settings

NCT00765726

TERMINATED Phase 2

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546

COMPLETED Phase 1

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

NCT00810758

COMPLETED Phase 1

Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

NCT00800956

COMPLETED Phase 1

Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer

NCT00768755

COMPLETED Phase 3

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652

COMPLETED Phase 1

A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

NCT00832052

COMPLETED Phase 2

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

NCT00797108

COMPLETED NA

A Study to Compare Two Ways of Completing Pain and Sleep Questions and to Evaluate a New Daily Questionaire for Assessing Fatigue in Fibromyalgia Patients

NCT00819624

COMPLETED Phase 1

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

NCT00821249

COMPLETED Phase 1

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

NCT00838058

COMPLETED Phase 1

Radiolabel ADME (Absorption, Distribution, Metabolism, and Excretion) Study Of [14C] PF-00868554 In Healthy Adult Male Subjects

NCT00823745

COMPLETED Phase 3

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132

COMPLETED

Study Evaluating Changes In Mammographic Breast Density

NCT00774267

TERMINATED Phase 1

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

NCT00800280

TERMINATED Phase 2

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

NCT00784693

TERMINATED Phase 2

A Study of ARRY-371797 in Patients With Active Ankylosing Spondylitis

NCT00811499

COMPLETED Phase 1

A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks

NCT00728390

COMPLETED Phase 2

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046

COMPLETED Phase 2

Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD

NCT00752557

COMPLETED Phase 3

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

NCT00761631

COMPLETED Phase 3

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

NCT00712348

COMPLETED Phase 2

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934

COMPLETED Phase 3

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

NCT00798707

COMPLETED Phase 1

A Study Evaluating The Absorption Of Varenicline Into The Body From A Varenicline Solution And A Varenicline Patch Applied To The Skin

NCT00774605

TERMINATED Phase 2

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NCT00809679

TERMINATED Phase 2

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

NCT00707239

TERMINATED Phase 3

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

NCT00795639

COMPLETED Phase 3

Tanezumab in Osteoarthritis Of The Hip

NCT00744471

COMPLETED Phase 1

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NCT00788294

COMPLETED Phase 1

A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

NCT00788047

COMPLETED Phase 1

Safety And Pharmacokinetics Study Of PF-04287881 In Healthy Adults

NCT00793000

COMPLETED Phase 1

A Study To Investigate The Pharmacokinetics, Safety And Tolerability Of An Intravenous And Oral Form Of A Compound In Subjects With Varying Degrees Of Renal Impairment And Normal Renal Function

NCT00759564

COMPLETED Phase 1

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

NCT00784719

COMPLETED Phase 1

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

NCT00799006

COMPLETED Phase 1

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

NCT00800618

COMPLETED Phase 2

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

NCT00769067

COMPLETED

Observational Study Assessing the Impact of Exposure to THROMBIN-JMI® on Coagulation Parameters.

NCT00775398

COMPLETED Phase 2

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

NCT00663026

COMPLETED Phase 2

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

NCT00690378

TERMINATED Phase 3

Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater

NCT00359632

COMPLETED

Arthroscopic Surgical Outcome Study In Subjects With Rotator Cuff Tears

NCT00739947

COMPLETED Phase 2

Topical CP-690,550 For Chronic Plaque Psoriasis

NCT00678561

COMPLETED Phase 1

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics

NCT00886821

COMPLETED Phase 1

Cumulative Irritation Test

NCT00781664

TERMINATED Phase 3

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

NCT00735267

COMPLETED Phase 3

An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain

NCT00726388

COMPLETED Phase 2

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

NCT00721409

COMPLETED Phase 3

Tanezumab in Osteoarthritis of the Knee

NCT00733902

COMPLETED Phase 3

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

NCT00678392

← Previous Page 27 of 37 Next →

Phase Distribution

PhaseTrial count
Phase 1 703
Phase 2 470
Phase 3 411
Phase 4 93

What is open in the Pfizer pipeline

106 recruiting of 1,845 indexed (6% open); 1,335 completed (72%).

Phase mix: 504 late (III/IV) vs 1,173 early (I/II) (early-phase heavy).

Top condition: Healthy (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Pfizer: open-pipeline peers nationwide

Peers matched on 1,845 registered trials and 6% open enrollment, not the therapeutic-area sidebar.

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share PfizerMemorial Sloan Kettering Cancer CenterStanford UniversityDuke UniversityUniversity of California, San FranciscoPacira PharmaceuticalsBioDelivery Sciences InternationalColgate PalmoliveDurham VA Medical Center
Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pfizer sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,845 trials (± recruiting share)

Sponsors near 6% open enrollment (± trial volume)

What to do with this Pfizer page

1,845 registered trials is a research-attention snapshot, not an endorsement of Pfizer or any single study.

  • 106 of Pfizer's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Healthy is the condition Pfizer studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer pipeline card: 1,845 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.